DiviTum® TKa is a blood-based biomarker test that monitors and predicts treatment response in hormone receptor-positive metastatic breast cancer. The test measures thymidine kinase activity (TKa) which reflects cell proliferation.
FDA-approved treatment guidance for your cancer
The free app that helps you manage your cancer care with confidence
Our recent collaboration with Outcomes4Me
The only direct-to-patient digital platform powered with the clinical, evidence-based knowledge. Outcomes4Me gather guidance on treatment options, typically meant for your oncologist, and translate it so you as patient can understand.
Biovica is a Swedish biotech company founded in 2009, committed to developing and commercializing novel blood-based biomarker assays. Our initial focus is breast cancer, a disease responsible for over 685,000 deaths a year (BCRF, 2022). We work with leading cancer institutes, collaborative groups, and pharmaceutical companies on product development with the aim of improving outcomes and lowering costs.
Event Calendar
See our events
Take a look at our Event Calendar. Meet us at upcoming conferences and schedule a meeting with us for the events.
Next-level mBC Monitoring
References:
